Axonics Modulation Technologies Inc represents a strong commitment to providing innovative medical solutions for patients with urinary and bowel dysfunction. The company's corporate philosophy revolves around advancing patient care through technological advancements. Axonics Modulation Technologies Inc focuses on developing and commercializing innovative products that aim to improve the quality of life for individuals suffering from functional disorders. With a comprehensive portfolio of neurostimulation systems, Axonics Modulation Technologies Inc aims to offer effective and sustainable treatment options. This commitment to patient-centered care and technological innovation sets Axonics Modulation Technologies Inc apart in the healthcare industry.

Axonics Modulation Technologies Inc is primarily present in multiple countries and regions. The company has a global presence, with operations and partnerships in various parts of the world. Some key markets where Axonics Modulation Technologies Inc is active include the United States, Europe, Canada, Australia, and certain countries in the Asia Pacific region. With its innovative medical devices and solutions, Axonics Modulation Technologies Inc is committed to improving the lives of patients worldwide.

Axonics Modulation Technologies Inc has achieved several significant milestones. Firstly, the company received FDA approval for its rechargeable sacral neuromodulation (SNM) system, which provides therapy for overactive bladder and urinary retention. Secondly, Axonics Modulation Technologies Inc successfully completed its initial public offering (IPO) in November 2018, raising approximately $120 million. Additionally, the company announced positive clinical trial results demonstrating the safety and effectiveness of its SNM system. Furthermore, Axonics Modulation Technologies Inc expanded its global presence by entering into multiple distribution agreements in Europe and other international markets. These milestones highlight the company's success in product development, market expansion, and regulatory accomplishments.

Axonics Modulation Technologies Inc is a prominent medical technology company specializing in the development and commercialization of innovative bladder and bowel management solutions. Founded in 2013, Axonics utilizes advanced neuromodulation technology to provide patients with long-lasting and effective treatment options for overactive bladder and fecal incontinence. The company's cutting-edge products, such as the Axonics r-SNM System, offer safe and durable solutions for patients seeking relief from these debilitating conditions. Axonics Modulation Technologies Inc has quickly gained recognition in the medical field for its dedication to improving the quality of life for individuals suffering from bladder and bowel dysfunction.

The main competitors of Axonics Modulation Technologies Inc in the market include Medtronic, Boston Scientific, and Nevro Corp.

Axonics Modulation Technologies Inc is primarily active in the medical device industry. They specialize in the development and commercialization of innovative products for the treatment of urinary and bowel dysfunction. Axonics Modulation Technologies Inc prides itself on providing advanced and minimally invasive solutions using neurostimulation technology. With a focus on improving patients' quality of life, Axonics Modulation Technologies Inc sets itself apart in meeting the growing demand for effective and long-lasting treatment options. As a prominent player in the medical device sector, Axonics Modulation Technologies Inc continues to drive advancements and deliver exceptional solutions for patients in need.

Axonics Modulation Technologies Inc's business model revolves around developing and commercializing innovative medical devices for the treatment of various urinary and bowel dysfunctions. The company primarily focuses on the design, manufacturing, and marketing of its implantable neuromodulation devices, which are targeted towards patients suffering from overactive bladder, urinary retention, and fecal incontinence. By providing technologically advanced products, Axonics aims to improve the quality of life for individuals affected by these conditions. The company's dedication to addressing unmet medical needs and delivering clinically proven solutions has established Axonics Modulation Technologies Inc as a leader in the field.

Pašreizējais KGV Axonics nevar tikt aprēķināts.

KUV šobrīd Axonics nevar aprēķināt.

AlleAktien kvalitātes vērtējums Axonics ir 2/10.

gaidāmā Axonics apgrozījums ir 550,73 milj. USD.

gaidāmā Axonics peļņa ir 42,80 milj. USD.

Axonics Modulation Technologies Inc is a US company that develops and manufactures medical technology for the treatment of chronic diseases of the nervous system. Axonics' business model is to provide high-quality, innovative products for patients suffering from incontinence and other disorders of the peripheral nervous system. Axonics specializes in the development and marketing of implanted devices for electrical stimulation of the nervous system. These devices, known as the Axonics Neuromodulation System, aim to stimulate nerve signals and improve the functioning of the nervous system. The Axonics Neuromodulation System includes a neurostimulating electrode placed directly on the target nerve, and a small battery that is implanted near the electrode implant. Using programmer devices programmed by doctors, patients can select different therapy programs to achieve the best results. The Axonics Neuromodulation System offers an effective alternative to medication for the treatment of chronic diseases of the peripheral nervous system. It can significantly improve quality of life and reduce symptoms, particularly for patients who do not respond to medication or are affected by its side effects. In addition to developing neurostimulation devices, Axonics is also involved in research and development of technologies to improve the effectiveness of neuromodulation treatments. This includes continuous monitoring programs of the power supply of the Axonics Neuromodulation System to ensure that the device is always adequately powered. Furthermore, Axonics is engaged in the development of imaging and diagnostic procedures to improve the diagnosis of peripheral nervous system diseases. This includes imaging technologies that allow better visualization of nerves and the brain, as well as procedures to measure the activity of the nervous system. Overall, Axonics' business model targets individuals with chronic diseases of the peripheral nervous system who are seeking effective and safe methods to improve their quality of life. With its innovative products and technologies, Axonics has the potential to revolutionize the treatment of incontinence and other peripheral nervous system disorders and help millions of people worldwide.

Axonics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Axonics vai uzņēmums nedod dividendes.

Axonics ISIN ir US05465P1012.

Axonics WKN ir A2N7B2.

Axonics simbols ir AXNX.

Pēdējo 12 mēnešu laikā Axonics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Axonics plāno maksāt dividendes 0 USD apmērā.

Axonics pašreizējā dividendu rentabilitāte ir .

Axonics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Axonics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Axonics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Axonics apmērā 0 USD, kas tika izmaksāta 23.09.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 23.09.2025..

Pēdējās dividendes izmaksa notika 23.09.2025..

Gadā 2024, Axonics izmaksāja 0 USD dividendes.

Axonics dividendes tiek izmaksātas USD.